Health Condition 1: - Health Condition 2: A00-B99- Certain infectious and parasitic diseases
Conditions
Interventions
None listed
Sponsors
Datar Cancer Genetics Private Limited
Eligibility
Inclusion criteria
Inclusion criteria: � High risk patients (patients with prolonged severe neutropenia, receiving corticosteroids or T-cell suppressor, recipients of allogeneic Hematopoietic stem-cell transplantation (HSCT), or inherited severe immunodeficiency) � Patients with other predisposing factors of invasive mould disease (Uncontrolled blood sugars, known diabetic on steroids , Acquired immunodeficiency syndrome (AIDS), haematological malignancies or solid tumours, prolonged Intensive Care Unit, or hospital stay abnormal D Dimer test). � Patients already diagnosed with probable or proven mucormycosis irrespective of underlying conditions, including patients referred from other centers.
Exclusion criteria
Exclusion criteria: � Presence of any medical condition that would not allow collection of blood samples for the Real-time polymerase chain reaction test. � History of documented, successfully treated, prior Mucormycosis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To diagnose early Mucormycosis and assess the sensitivity and specificity of the testTimepoint: Date of first enrollment - 15th June 2021 Target to achieve sample size - In three months Study completion - As per study criteria | — |
Secondary
| Measure | Time frame |
|---|---|
| Any other incidental or significant observationTimepoint: Six months from completion of study | — |
Countries
India
Contacts
Public ContactDr Ashwini Ghaisas
Datar Cancer Genetics Private Limited
Outcome results
None listed